India's Biocon exits enzymes business

Biocon sells its enzymes business to Denmark's Novozymes for $115 million in an attempt to become a more focussed biotechnology player.

Indian biotechnology player Biocon announced on July 18 that it will sell its enzymes business to Novozymes of Denmark for $115 million.

Biocon is currently in the bio-pharmaceuticals, contract research, clinical research and enzymes businesses. Its enzymes division offers a range of industrial enzymes, food additives, process aids and enzymes for the juice and wine industries. The divestiture is designed to sharpen BioconÆs focus on its bio-pharmaceuticals business, which includes active pharmaceutical ingredients, biologicals and proprietary molecules.

Of the total...

To continue reading, please login or register for free

Click for more on: biocon | novozymes | enzymes

Print Edition

FinanceAsia Print Edition

CONFERENCES

  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...